Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 14, 485 - 487 (2008)
doi:10.1038/nm0508-485
-adrenergic signaling in heart failure—adapt or die
Thomas Eschenhagen1
- Thomas Eschenhagen is at the Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
e-mail: t.eschenhagen@uke.uni-hamburg.de
Abstract
About 25% of the African-American population carries a gene variant that seems to protect against heart failure. The findings may have implications for the use of 
-blockers (pages 510–517).
A report in this issue of Nature Medicine1 identifies a gene variant that seems to protect against the progression of heart failure. The gene, GRK5, encodes a G protein–coupled receptor kinase (GRK) that participates in signaling through -adrenergic receptors, the targets of -blockers.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failureNature Medicine Article (01 May 2008)
β 1 -adrenergic receptor polymorphisms confer differential function and predisposition to heart failureNature Medicine Article (01 Oct 2003)
